Literature DB >> 7011979

Amplified migration inhibition effect.

J R Philp, A L Huffman, L R DeChatelet, J E Johnson.   

Abstract

When tuberculin-sensitive peritoneal exudate cells are incubated in a culture flask with tuberculin purified protein derivative, macrophage inhibition factor and other lymphokines are released into the culture medium. We have described how, if incubation is carried out in a stationary conical culture tube, intercellular contact between the peritoneal exudate cells is facilitated as the cells sediment into a pellicle at the bottom of the tube. This results in augmented release of inhibitory lymphokines into the supernatant culture medium with titers up to 10(9) times greater than those obtained by conventional culture methods using a flatbottomed culture dish or flask. When such high-titered inhibitory supernatants were subjected to fractionation by sequential Amicon ultrafiltration, two clearly distinct macrophage-inhibitory lymphokines were found. The first was present, after fractionation, in a titer of 10(12), had a molecular weight in the range of 50,000 to 100,000, and was heat stable at 56 degrees C for 1 h. This moiety is probably identical to guinea pig macrophage inhibition factor. Unexpectedly, a second heat-labile inhibitory substance with a molecular weight between 500 and 1,000 was found in a titer of 10(4) after fractionation. This low-molecular-weight, heat-labile material may represent a new lymphokine with a direct inhibitory action on macrophage migration. Theoretically, the data are also consistent with the possibility that it could act as a chemical immunotransmitter which stimulates amplified production of macrophage inhibition factor by lymphocytes within the cell pellicle and leads indirectly to inhibition of macrophage migration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7011979      PMCID: PMC551166          DOI: 10.1128/iai.29.2.609-616.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

1.  Surface topography and interactions between mouse peritoneal cells allowed to settle on an artificial substrate: observations by scanning electron microscopy.

Authors:  J M Orenstein; E Shelton
Journal:  Exp Mol Pathol       Date:  1976-04       Impact factor: 3.362

2.  Amplified migration inhibition effect.

Authors:  J R Philp; A L Huffman; J E Johnson
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

3.  Chemical characterization of products of activated lymphocytes.

Authors:  C Sorg; W Klinkert
Journal:  Fed Proc       Date:  1978-11

4.  Amplification of migratory inhibition factor production during the first 48 hours of exposure to antigen.

Authors:  J R Philp; J E Johnson; J C Spencer
Journal:  Infect Immun       Date:  1973-11       Impact factor: 3.441

5.  Macrophage migration.

Authors:  J R David
Journal:  Fed Proc       Date:  1968 Jan-Feb

6.  Enhancement of carrier-mediated transport after immunologic activation of peritoneal macrophages.

Authors:  P F Bonventre; D Straus; R E Baughn; J Imhoff
Journal:  J Immunol       Date:  1977-05       Impact factor: 5.422

7.  Macrophage-lymphocyte interaction. I. Characteristics of the antigen-independent-binding of guinea pig thymocytes and lymphocytes to syngeneic macrophages.

Authors:  P E Lipsky; A S Rosenthal
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

8.  The production of migration inhibition factor by B and T cells of the guinea pig.

Authors:  T Yoshida; H Sonozaki; S Cohen
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

  8 in total
  2 in total

1.  Lymphokine-induced mycobacteriostatic activity in mouse pleural macrophages.

Authors:  A Zlotnik; A J Crowle
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

2.  Amplified lymphokine production phenomenon confirmed by a macrophage 2-D-[3H]deoxyglucose transport assay.

Authors:  J G McCormack; A L Moore; J E Johnson; J R Philp
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.